Prognostic Value of Circulating Tumor DNA for Recurrence Risk in Stage III Colorectal Cancer: A Systematic Review and Meta-Analysis.
[BACKGROUND] Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection and recurrence risk stratification in colorectal cancer (CRC).
- p-value P < .00001
- 95% CI 3.45-5.58
- HR 6.56
- RR 4.39
- 연구 설계 meta-analysis
APA
Aliyeva T, Siddiqui H, et al. (2026). Prognostic Value of Circulating Tumor DNA for Recurrence Risk in Stage III Colorectal Cancer: A Systematic Review and Meta-Analysis.. Clinical colorectal cancer, 25(1), 77-86. https://doi.org/10.1016/j.clcc.2025.10.004
MLA
Aliyeva T, et al.. "Prognostic Value of Circulating Tumor DNA for Recurrence Risk in Stage III Colorectal Cancer: A Systematic Review and Meta-Analysis.." Clinical colorectal cancer, vol. 25, no. 1, 2026, pp. 77-86.
PMID
41266203
Abstract
[BACKGROUND] Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for minimal residual disease (MRD) detection and recurrence risk stratification in colorectal cancer (CRC). However, its prognostic significance in stage III CRC remains incompletely defined. This meta-analysis aimed to evaluate the association between postoperative ctDNA positivity and recurrence risk in patients with stage III CRC.
[METHODS] PubMed, Embase, and the Cochrane Library were searched for potentially eligible studies published up to April 2025. Pooled risk ratio (RR) and pooled hazard ratio (HR) were calculated to evaluate recurrence rate and the prognosis of recurrence-free survival (RFS) following CRC surgery and ACT. Meta-analysis was performed using a random-effects model.
[RESULTS] A total of ten studies involving 2461 stage III CRC patients were included. Postoperative ctDNA positivity was significantly associated with an increased risk of recurrence (RR = 4.39, 95% CI, 3.45-5.58, P < .00001) and a poorer RFS (HR = 6.56, 95% CI, 4.80-8.98, P < .00001). The pooled analysis showed that ctDNA-positive patients had a significantly higher risk of recurrence following ACT (RR = 4.80, 95% CI, 3.17-7.26, P < .00001) and a worse RFS (HR = 10.00, 95% CI, 4.84-20.66, P < .00001).
[CONCLUSION] Postoperative ctDNA positivity is a strong prognostic marker of recurrence in patients with stage III CRC and could guide individualized surveillance and adjuvant therapy decisions. Further prospective studies are warranted to validate its routine clinical use.
[METHODS] PubMed, Embase, and the Cochrane Library were searched for potentially eligible studies published up to April 2025. Pooled risk ratio (RR) and pooled hazard ratio (HR) were calculated to evaluate recurrence rate and the prognosis of recurrence-free survival (RFS) following CRC surgery and ACT. Meta-analysis was performed using a random-effects model.
[RESULTS] A total of ten studies involving 2461 stage III CRC patients were included. Postoperative ctDNA positivity was significantly associated with an increased risk of recurrence (RR = 4.39, 95% CI, 3.45-5.58, P < .00001) and a poorer RFS (HR = 6.56, 95% CI, 4.80-8.98, P < .00001). The pooled analysis showed that ctDNA-positive patients had a significantly higher risk of recurrence following ACT (RR = 4.80, 95% CI, 3.17-7.26, P < .00001) and a worse RFS (HR = 10.00, 95% CI, 4.84-20.66, P < .00001).
[CONCLUSION] Postoperative ctDNA positivity is a strong prognostic marker of recurrence in patients with stage III CRC and could guide individualized surveillance and adjuvant therapy decisions. Further prospective studies are warranted to validate its routine clinical use.
MeSH Terms
Humans; Colorectal Neoplasms; Circulating Tumor DNA; Neoplasm Recurrence, Local; Biomarkers, Tumor; Prognosis; Neoplasm Staging; Neoplasm, Residual; Risk Assessment; Disease-Free Survival
같은 제1저자의 인용 많은 논문 (2)
- The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
- Electrophysiological Evidence of Contralateral Neuromuscular Effects Following Long-Term Botulinum Toxin Therapy in Hemifacial Spasm.